Pelabresib in MPNs: Immune Profiles of Responders vs. Non-responders

Panelists discuss the immune profiles of responders vs non-responders to pelabresib in myeloproliferative neoplasms (MPNs).

EP: 1.Myelofibrosis: Background, Risk Stratification, and Treatment Decision-Making

EP: 2.Approved and Investigational Agents for Myelofibrosis

EP: 3.Disease Modification Strategies and Unmet Needs in Myelofibrosis

EP: 4.MANIFEST-2: Pelabresib in Myelofibrosis: MOA, Study Design, and Spleen Volume Reduction

EP: 5.Disease- Modifying Biomarker Data in the MANIFEST-2 Study Investigating Pelabresib

EP: 6.Safety Profile of the Pelabresib and Ruxolitinib Combination in Myelofibrosis

Now Viewing

EP: 7.Pelabresib in MPNs: Immune Profiles of Responders vs. Non-responders

Recent Videos